Welgwiyan Secures Tens of Millions in Series A Funding to Enhance Diverse Biomedical Engineering Solutions

VCBeat has learned that Suzhou Wanguiyuan Precision Technology Co., Ltd. (hereinafter referred to as “Wanguiyuan”) recently completed a Series A financing round amounting to tens of millions of yuan. The round was led by Dongyun Venture Capital, with participation from Qianrong Chuanghe Capital and Sihai New Materials Fund. The proceeds will be used to enhance the production capacity of existing product lines, develop new product pipelines, construct a new production base, and expand the R&D team.

Suzhou Wanguiyuan Precision Technology Co., Ltd. is located in the Wujiang Economic and Technological Development Zone of Suzhou City. It is aCore offerings for in vitro diagnostics, medical devices, life sciences, and biopharmaceutical companiesProcesses, Equipment, and SolutionsOne-Stop Service Provider for Comprehensive Engineering Solutions。

Leveraging years of accumulated expertise in technological innovation and marketing, the company has mastered multiple core technologies in the biomedical field, such as micro-volume control technology and sterile environment control technology. Its platform-based technical processes, extensive practical experience, and a professional, high-efficiency technical team enable Suzhou Wanguiyuan Precision Technology Co., Ltd. to rapidly respond to diverse customer needs. The company designs, manufactures, and continuously optimizes automated production equipment with proprietary processes, empowering clients to enhance their core competitiveness in both domestic and international markets through faster delivery and superior product quality. Consequently, numerous listed companies and renowned biopharmaceutical enterprises have chosen Suzhou Wanguiyuan as their provider of automated equipment and one-stop services.

Suzhou Wanguiyuan's "Automated Production Line for Microfluidic Chips"”Breaking the foreign technological monopoly and thoroughly resolving industry challenges to ensure that mass production of microfluidic chips is no longer constrained by external bottlenecks. The “multi-chamber fully automatic high-speed filling line,” tailor-made for epidemic prevention and control enterprises, has addressed the challenge of meeting rapid, large-scale demand for anti-epidemic supplies. To date, the high-speed lines delivered by Wanguiyuan have cumulatively produced over 50 million units of nucleic acid testing reagents, demonstrating tangible support for epidemic prevention efforts. Wanguiyuan has established a presence in both the biopharmaceutical and high-value medical device sectors, with its expanded product portfolio now including “high-end automated production lines for wet films in sterile environments.””“Automated Production Base Station for Neurointerventional Devices”“Fully Automated Cell Culture Production and Preparation”and other product pipelines under development. In particular, the biological cell therapy market is poised for explosive growth in the future, and the company’s customized automated preparation systems for cell culture will surely inject new momentum into the cell therapy industry.

Mr. Zhang Cangmin, Founder of WanguiyuanStatement: With the continued rapid growth of the life sciences and healthcare industries, market demand for high-quality upstream products is increasing. Since its establishment, Wanguiyuan has been dedicated to the research, development, and manufacturing of core upstream tools, offering a diverse product portfolio and comprehensive solutions for biomedical engineering. Moving forward, we will continue to deepen our presence in the biopharmaceutical sector, strengthen talent development, and increase investment in innovation and R&D, thereby enhancing the core competitiveness of our downstream customers’ products.

Mr. Lu, Dongyun Venture CapitalStatement: As the state-owned investment platform of Wujiang Economic and Technological Development Zone in Suzhou, Dongyun Venture Capital has been committed to identifying and investing in high-tech projects in niche sectors that break through international blockades for the development zone. Dongyun Venture Capital has consistently focused on laying out the biomedical industry chain, gradually forming a comprehensive investment portfolio covering innovative drug platforms, biological raw materials, in vitro diagnostics (IVD), medical devices, and equipment. Wanguiyuan, as Dongyun’s key strategic layout in the upstream tools sector of biomedicine, possesses fully independent intellectual property rights for its existing product lines, with multiple key technical indicators matching or even surpassing the performance of world-class products. The company is dedicated to advancing precision medicine and supporting life sciences and clinical medicine. It looks forward to sustaining innovation in the future, fully leveraging the performance characteristics and advantages of its platform, and becoming a Chinese enterprise with global core competitiveness in providing comprehensive solutions for diverse biomedical engineering, thereby serving the world.

Sihai New Materials RepresentativeIn the field of in vitro diagnostics (IVD) within life sciences, due to technical barriers, there are only a handful of equipment manufacturers capable of providing complete solutions for microfluidic chips and high-value medical consumables. The next five years will witness a flourishing landscape in the IVD sector, where upstream equipment suppliers will serve as the key driving force. Over the past few years since its establishment, Suzhou Wanguiyuan Precision Technology Co., Ltd. has continuously iterated its technologies and withstood market tests. It is poised to become one of the leading enterprises in this field. We look forward to Wanguiyuan’s continuous self-breakthroughs and its emergence as a core pillar of the industry.

Qianrong Chuanghe CapitalObservation: Currently, the production of in vitro diagnostics (IVD) and high-value medical consumables remains predominantly manual or semi-automated. Against the backdrop of centralized volume-based procurement, medical manufacturers face immense pressure to reduce costs, making the replacement of manual labor with automation a major industry trend. The healthcare sector is characterized by numerous specialized segments and high professional barriers; consequently, high-end medical automated production lines rely heavily on imports and command premium prices. The core team of Suzhou Wanguiyuan Precision Technology Co., Ltd. possesses extensive industry experience and strong capabilities in diverse engineering solutions. It has successfully delivered multiple domestic first-of-their-kind automated production lines for industry benchmark clients such as Bohui Innovation, Ustar Biotechnologies, and Tailin Bioengineering, thereby securing a first-mover advantage. We believe that with the continuous expansion of Wanguiyuan’s new product lines and the accumulation of delivery case studies, the company is poised for rapid future growth.

In 2008, to accelerate the rapid development of science and technology innovation enterprises and create a new platform for innovative industrial carriers in the Wujiang Economic Development Zone, Wujiang Dongyun Venture Capital Co., Ltd. was established. Since its inception, Dongyun Venture Capital has supported a cohort of “little giant” tech companies characterized by high technological content, strong growth potential, sustainable development capabilities, and high local retention. This initiative has provided ample room for development during the Wujiang Economic Development Zone’s strategic transformation, industrial upgrading, and structural optimization, facilitating the landing of more high-end, high-quality projects and the aggregation of top-tier talent, thereby enhancing the competitiveness of this national-level economic and technological development zone. To date, Dongyun Venture Capital has internally cultivated three listed companies and nearly ten companies preparing for initial public offerings, achieving a current financial return on investment of over 50 times, with the potential to exceed 100 times.

Sihai New Materials, established in 2015 and leveraging the support of the Shenzhen New Materials Industry Association, specializes in new materials, supporting equipment, and material application investments. Its investment portfolio spans sectors such as lithium-ion batteries, hydrogen energy, novel energy storage, third-generation semiconductors, and life sciences.

Jiangsu Qianrong Investment Holding Group is a comprehensive investment holding group that covers the entire investment lifecycle and industry chain, including angel investment, venture capital (VC), private equity (PE), mergers and acquisitions (M&A), industrial fund-of-funds, secondary market investments, and quantitative hedge strategies. The group has invested in more than 40 technology companies and four financial institutions, among which 12 have been listed on the Shanghai and Shenzhen Stock Exchanges as well as the Hong Kong Stock Exchange. Notable success stories include Tian Shun Wind Energy, Victory Precision, Neway Valve, Hengjiu Optoelectronics, Medisystem, Zhongji Innolight, Canz Medical, and Xinhan New Materials. In the life and health sector, the group has also invested in projects such as Danuo Pharmaceutical, Zhongtian Medical, Lancet Robotics, and Ruitouch Technology.